Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
24 hedge funds and large institutions have $25.9M invested in Biora Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 9 closing their positions.
1,356% more call options, than puts
Call options by funds: $2.34M | Put options by funds: $161K
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
96% more capital invested
Capital invested by funds: $13.2M → $25.9M (+$12.7M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
20% less funds holding
Funds holding: 30 → 24 (-6)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Athyrium Capital Management
New York
|
+$29.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$110K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$64.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$26.5K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$13.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$2.38M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$340K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$148K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$84.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$54.7K |
BIOR Hedge Fund Activity: Q3 2023 in Review
24 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q3 2023, worth a combined $25.9M — up 96% from $13.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BIOR and 3 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 10 added.
The largest buyer was Athyrium Capital Management, adding an estimated $29.6M. The largest seller was Anson Funds Management, exiting entirely with an estimated $2.38M sold.
- 24 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q3 2023, down from 30 in Q2 2023.
- Funds reported $25.9M of Biora Therapeutics, Inc. Common Stock stock for Q3 2023, up 96% quarter-over-quarter.
- 3 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q3 2023 and 9 closed out, a net change of -6 holders.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q3 2023 was Athyrium Capital Management, an estimated $29.6M added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q3 2023 was Anson Funds Management, an estimated $2.38M sold.
Based on aggregated 13F filings for Q3 2023.